Long-term CD4+ T-cell Count Changes After Switching HIV Treatments
Author Information
Author(s): Torti Carlo, d'Arminio-Monforte Antonella, Pozniak Anton L, Lapadula Giuseppe, Cologni Giuliana, Antinori Andrea, De Luca Andrea, Mussini Cristina, Castagna Antonella, Cicconi Paola, Minoli Lorenzo, Costantini Andrea, Carosi Giampiero, Liang Hua, Cesana Bruno M
Primary Institution: University of Brescia, Italy
Hypothesis
Does switching from protease inhibitor-based regimens to non-protease inhibitor regimens affect CD4+ T-cell recovery in HIV patients?
Conclusion
Switching from first-line protease inhibitor regimens to NNRTI or NRTI-based regimens did not impair the long-term CD4+ T-cell trend.
Supporting Evidence
- Patients switched to NRTI-only regimens showed greater CD4+ count increases due to higher baseline counts.
- Only 6.9% of patients showed a decrease in CD4+ counts within 180 days of switching.
- Statistical analyses indicated no significant differences in CD4+ trends after switching treatments.
Takeaway
This study looked at how changing HIV treatments affects a type of immune cell called CD4+ T-cells. It found that switching treatments didn't hurt the recovery of these cells over time.
Methodology
Retrospective inter-cohort study analyzing CD4+ T-cell counts in patients who switched from PI-based regimens to NNRTI or NRTI-only regimens.
Potential Biases
Potential selection bias favoring the NRTI group due to exclusion of patients who continued on PI.
Limitations
The study was not randomized, which may introduce selection bias, and it relied on a 500 copies/ml cut-off for undetectable HIV RNA.
Participant Demographics
896 patients, median age 39 years, predominantly male (79.9%), with various risk factors for HIV acquisition.
Statistical Information
P-Value
P = 0.0024
Confidence Interval
95%CI = 0.81-0.89
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website